GSK wins new reprieve as Hikma's generic Advair delayed again

(Reuters) – GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *